WCM Investment Management LLC Acquires 165,157 Shares of Biohaven Ltd. (NYSE:BHVN)

WCM Investment Management LLC raised its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 154.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 271,822 shares of the company's stock after purchasing an additional 165,157 shares during the quarter. WCM Investment Management LLC owned 0.27% of Biohaven worth $6,535,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Parallel Advisors LLC lifted its stake in Biohaven by 319.8% during the 1st quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock valued at $33,000 after acquiring an additional 1,036 shares during the period. Amalgamated Bank boosted its position in Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after purchasing an additional 527 shares in the last quarter. KBC Group NV grew its stake in shares of Biohaven by 35.0% during the 1st quarter. KBC Group NV now owns 4,560 shares of the company's stock worth $110,000 after purchasing an additional 1,183 shares during the period. US Bancorp DE grew its position in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after buying an additional 798 shares during the period. Finally, Quarry LP purchased a new position in Biohaven in the fourth quarter valued at $112,000. Hedge funds and other institutional investors own 88.78% of the company's stock.

Biohaven Price Performance

NYSE BHVN traded down $0.13 on Friday, reaching $14.63. The company had a trading volume of 753,892 shares, compared to its average volume of 1,293,377. Biohaven Ltd. has a 1 year low of $13.87 and a 1 year high of $55.70. The firm has a market capitalization of $1.49 billion, a PE ratio of -1.56 and a beta of 0.91. The firm has a 50-day moving average of $16.84 and a 200-day moving average of $26.93.

Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BHVN. Robert W. Baird reduced their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. Cantor Fitzgerald raised shares of Biohaven to a "strong-buy" rating in a research note on Tuesday, May 13th. William Blair upgraded shares of Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Morgan Stanley decreased their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the stock a "buy" rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Biohaven currently has an average rating of "Buy" and a consensus target price of $58.46.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.